<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01475136</url>
  </required_header>
  <id_info>
    <org_study_id>12677</org_study_id>
    <secondary_id>H8Y-MC-HBCH</secondary_id>
    <secondary_id>2011-003033-34</secondary_id>
    <nct_id>NCT01475136</nct_id>
  </id_info>
  <brief_title>A Study of LY2140023 in Hepatically-Impaired Participants</brief_title>
  <official_title>A Single Dose Pharmacokinetic Study of LY2140023 in Subjects With Hepatic Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Denovo Biopharma LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Denovo Biopharma LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will explore how liver impairment affects blood levels of LY2140023 (a prodrug)&#xD;
      and its active metabolite (LY404039).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study included 4 groups, based on the Child-Pugh classification of hepatic impairment as&#xD;
      follows:&#xD;
&#xD;
      Group 1: Participants with normal hepatic function (Control); Group 2: Participants with mild&#xD;
      hepatic impairment (Child-Pugh class A); Group 3: Participants with moderate hepatic&#xD;
      impairment (Child-Pugh class B); and Group 4: Participants with severe hepatic impairment&#xD;
      (Child-Pugh class C).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics: Area Under the Concentration Time Curve (AUC) of LY2140023 and LY404039</measure>
    <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 9, 12, 16, 24, 36, and 48 hours postdose</time_frame>
    <description>LY404039 is the active metabolite of LY2140023. AUC from zero to infinity AUC(0-âˆž) is presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Maximum Observed Drug Concentration (Cmax) of LY2140023 and LY404039</measure>
    <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 9, 12, 16, 24, 36, and 48 hours postdose</time_frame>
    <description>LY404039 is the active metabolite of LY2140023.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Time of Maximal Concentration (Tmax) of LY2140023 and LY404039</measure>
    <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 9, 12, 16, 24, 36, and 48 hours postdose</time_frame>
    <description>LY404039 is the active metabolite of LY2140023.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Hepatic Insufficiency</condition>
  <arm_group>
    <arm_group_label>LY2140023</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single oral dose of 80 milligrams (mg) LY2140023 administered on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2140023</intervention_name>
    <arm_group_label>LY2140023</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male participants agree to use a reliable method of birth control during the study and&#xD;
             for 3 months following the last dose of LY2140023&#xD;
&#xD;
          -  Female participants of child-bearing potential who test negative for pregnancy at&#xD;
             screening and agree to use a reliable method of birth control for the duration of the&#xD;
             study and for at least 3 months after the last dose of LY2140023&#xD;
&#xD;
          -  Female participants who are postmenopausal. Postmenopausal is defined as no menses for&#xD;
             at least 1 year, or a plasma follicle stimulating hormone (FSH) value of greater than&#xD;
             40 units per liter (IU/L), unless the participant is taking hormone replacement&#xD;
             therapy&#xD;
&#xD;
          -  Have a body mass index (BMI) between 19 and 40 kilograms per square meter (kg/m^2),&#xD;
             inclusive at the time of screening&#xD;
&#xD;
          -  Have clinical laboratory test results within the normal reference range for the&#xD;
             population or investigator site, or results with acceptable deviations that are judged&#xD;
             to be not clinically significant by the investigator&#xD;
&#xD;
          -  Have sitting blood pressure and heart rate compatible with their disease state, as&#xD;
             determined by the investigator&#xD;
&#xD;
          -  Have venous access sufficient to allow for blood sampling as per the protocol&#xD;
&#xD;
          -  Are reliable and willing to make themselves available for the duration of the study&#xD;
             and are willing to follow study procedures&#xD;
&#xD;
          -  Have given written informed consent approved by Lilly and the ethical review board&#xD;
             (ERB) governing the site&#xD;
&#xD;
          -  Control participants that have normal hepatic function, as determined by medical&#xD;
             history and physical examination&#xD;
&#xD;
          -  Hepatically-impaired participants that have stable hepatic impairment (for example,&#xD;
             alcoholic, posthepatitis, biliary cirrhosis, or cryptogenic) classified as Child-Pugh&#xD;
             class A, B, or C (mild, moderate, or severe impairment) who are considered acceptable&#xD;
             for participation in the study by the investigator&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Are currently enrolled in, have completed or discontinued within the last 90 days from&#xD;
             last dosing of an investigational product (other than the investigational product used&#xD;
             in this study); or are concurrently enrolled in any other type of medical research&#xD;
             judged not to be scientifically or medically compatible with this study&#xD;
&#xD;
          -  Have known allergies to LY2140023, LY404039, related compounds, or any components of&#xD;
             the formulation&#xD;
&#xD;
          -  Have previously discontinued after receiving at least 1 dose of LY2140023 or completed&#xD;
             this study or any other study investigating LY2140023 and or LY404039&#xD;
&#xD;
          -  Have an abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of the&#xD;
             investigator, increases the risks associated with participating in the study&#xD;
&#xD;
          -  Have a history or presence of cardiovascular, respiratory, renal, gastrointestinal,&#xD;
             endocrine, hematological, or neurological disorders capable of significantly altering&#xD;
             the absorption (except cholecystectomy), metabolism, or elimination of drugs; of&#xD;
             constituting a risk when taking the study medication; or of interfering with the&#xD;
             interpretation of data&#xD;
&#xD;
          -  Have evidence of significant active neuropsychiatric disease (for example, manic&#xD;
             depressive illness, schizophrenia, or depression)&#xD;
&#xD;
          -  Participants who answer 'yes' to either Question 4 (Active Suicidal Ideation with Some&#xD;
             Intent to Act, Without Specific Plan) or Question 5 (Active Suicidal Ideation with&#xD;
             Specific Plan and Intent) on the &quot;Suicidal Ideation&quot; portion of the Columbia Suicide&#xD;
             Severity Rating Scale (C-SSRS), or answer &quot;yes&quot; to any of the suicide-related&#xD;
             behaviors (actual attempt, interrupted attempt, aborted attempt, preparatory act, or&#xD;
             behavior) on the &quot;Suicidal Behavior&quot; portion of the C-SSRS; and the ideation or&#xD;
             behavior occurred within the past 3 months&#xD;
&#xD;
          -  Have increased risk of seizures based on a history of:&#xD;
&#xD;
               -  One or more seizures (except for a single simple febrile seizure [lacking&#xD;
                  focality and lasting less than 15 minutes, not associated with a central nervous&#xD;
                  system (CNS) infection or severe metabolic disturbance] as a child between ages 6&#xD;
                  months to 5 years)&#xD;
&#xD;
               -  Head trauma with loss of consciousness or a post-concussive syndrome within 1&#xD;
                  year or lifetime history of head trauma with persistent neurological deficit&#xD;
                  (focal or diffuse)&#xD;
&#xD;
               -  CNS infection, uncontrolled migraine or transient ischemic attack (TIA) within 1&#xD;
                  year; stroke with persistent neurological deficit (focal or diffuse).&#xD;
                  Uncontrolled migraine is defined as migraine attacks that produce headache&#xD;
                  lasting up to 72 hours and are often accompanied by associated symptoms (nausea,&#xD;
                  photophobia, and phonophobia) that impair well-being and disrupt social&#xD;
                  functioning. TIA is defined as &quot;mini-stroke&quot; caused by temporary disturbance of&#xD;
                  blood supply to an area of the brain, which results in a sudden, brief decrease&#xD;
                  in brain function&#xD;
&#xD;
               -  CNS infection with persistent neurological deficit (focal or diffuse)&#xD;
&#xD;
               -  Brain surgery&#xD;
&#xD;
               -  Electroencephalogram (EEG) with paroxysmal (epileptiform) activity (isolated&#xD;
                  spikes waves, repetitive bursts of sharp waves, paroxysmal activity, frank&#xD;
                  seizures, spike-wave complexes, sharp-slow wave complexes, or as locally defined)&#xD;
&#xD;
               -  Brain structural lesion, including developmental abnormalities, as determined by&#xD;
                  examination or imaging studies (does not include hydrocephalus unless treated by&#xD;
                  shunt or resulting in neurological deficits)&#xD;
&#xD;
          -  Known substance dependence unless approved prescription medication such as opiates, or&#xD;
             known regular use of drugs of abuse and/or show positive findings on urinary drug&#xD;
             screening&#xD;
&#xD;
          -  Show evidence of human immunodeficiency virus (HIV) infection and/or positive human&#xD;
             HIV antibodies&#xD;
&#xD;
          -  Women who are pregnant or intend to get pregnant during the study or within 3 months&#xD;
             after the last dose of investigational product&#xD;
&#xD;
          -  Women who are breast feeding or lactating&#xD;
&#xD;
          -  Have donated blood of more than 500 milliliters (mL) within the last 3 months prior to&#xD;
             the screening&#xD;
&#xD;
          -  Are organ transplant participants or have taken immunosuppressants following any organ&#xD;
             transplant&#xD;
&#xD;
          -  Have shown signs of variceal bleeding during the last 2 months prior to screening&#xD;
             (except for participants with severe hepatic impairment, detailed in exclusion&#xD;
             criterion)&#xD;
&#xD;
          -  Show evidence of irritable bowel syndrome or chronic diarrhea&#xD;
&#xD;
          -  Have an average weekly alcohol intake that exceeds 21 units per week (males) and 14&#xD;
             units per week (females), and are participants unwilling to stop alcohol consumption&#xD;
             for 96 hours predose until after 48 hours post-dose (1 unit equals 12 ounces [oz] or&#xD;
             360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits)&#xD;
&#xD;
          -  Have a clinically significant abnormality in the neurological examination&#xD;
&#xD;
          -  Participants judged prior to dosing to be at suicidal risk by the investigator&#xD;
&#xD;
          -  Participants who are unwilling to refrain from smoking from midnight prior to dosing&#xD;
             until 6 hours postdose or are unable to abide by the Clinical Research Unit (CRU)&#xD;
             restrictions&#xD;
&#xD;
          -  Are on total parenteral nutrition (TPN)&#xD;
&#xD;
          -  Take oral anticoagulants for therapeutic use&#xD;
&#xD;
          -  Exhibit any other condition, which, in the opinion of the investigator would preclude&#xD;
             participation in the study&#xD;
&#xD;
          -  Show evidence of pruritus or skin exfoliation&#xD;
&#xD;
          -  Have an eosinophil count &gt;1.5 x 10^9/liter (L)&#xD;
&#xD;
          -  Have electrolyte imbalance alerts (clinically significant changes in calcium&#xD;
             magnesium, or sodium)&#xD;
&#xD;
          -  Control Participants:&#xD;
&#xD;
               -  Have any medically significant history of neurologic disease, cancer, or cardiac,&#xD;
                  respiratory, metabolic, hepatic, renal, gastrointestinal (except appendectomy),&#xD;
                  dermatological, venereal, hematological disorder or disease&#xD;
&#xD;
               -  Have creatinine clearance (CrCl) less than 80 milliliters per minute (mL/min), as&#xD;
                  calculated by the Cockcroft-Gault equation:&#xD;
&#xD;
        Men: [(140 - age) x (weight in kilograms [kg])] / [72 x (serum creatinine in mg/100 mL)];&#xD;
        or [(140 - age) x (weight in kg)] / [0.81 x (serum creatinine in micromoles per liter&#xD;
        [Î¼mol/L])] Women in both of the above equations: (x 0.85)&#xD;
&#xD;
          -  Show evidence of significant active neuropsychiatric disease in the opinion of the&#xD;
             investigator&#xD;
&#xD;
          -  Evidence of hepatitis B and/or positive hepatitis B surface antigen (HBsAg)&#xD;
&#xD;
          -  Show evidence of hepatitis C and/or positive hepatitis C antibody&#xD;
&#xD;
          -  Intend to use over-the-counter medication (including herbal remedies/health&#xD;
             supplements) within 7 days prior to dosing, or prescription medication (other than&#xD;
             hormone replacement therapy as described above) within 14 days prior to dosing&#xD;
&#xD;
               -  Mild Hepatic Impaired Participants (Child-Pugh A):&#xD;
&#xD;
          -  show evidence of any significant active disease other than that responsible for or&#xD;
             associated with hepatic impairment&#xD;
&#xD;
          -  have a platelet count of less than 50 x 10^9 cells/L, unless after consultation with&#xD;
             the Lilly Clinical Pharmacologist (CP), they are considered as acceptable for&#xD;
             participation in the study&#xD;
&#xD;
               -  Moderate and Severe Hepatic Impaired Participants (Child-Pugh B and C):&#xD;
&#xD;
          -  Show evidence of any significant active disease other than that responsible for or&#xD;
             associated with moderate or severe hepatic impairment&#xD;
&#xD;
          -  Have shown signs of spontaneous bacterial peritonitis within 6 months prior to dosing&#xD;
&#xD;
          -  Have severe hyponatremia&#xD;
&#xD;
          -  Show evidence of significant active neuropsychiatric disease&#xD;
&#xD;
          -  Have hepatic encephalopathy (Grades 2 to 4)&#xD;
&#xD;
          -  Have hemoglobin concentrations &lt;9.0 grams per deciliter (g/dL)&#xD;
&#xD;
          -  Show signs of hepatocellular carcinoma&#xD;
&#xD;
          -  Have a surgical portosystemic shunt&#xD;
&#xD;
          -  Have a platelet count of less than 40 x 10^9 cells/L (moderate impairment) or less&#xD;
             than 30 x 10^9 cells/L (severe impairment), unless after consultation with the Lilly&#xD;
             CP they are considered as acceptable for participation in the study&#xD;
&#xD;
          -  Have shown signs of variceal bleeding during the last 2 weeks prior to screening&#xD;
             (severe hepatic impaired participants only)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Munich</city>
        <zip>81241</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>BalatonfÃ¼red</city>
        <zip>8230</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Hungary</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>November 16, 2011</study_first_submitted>
  <study_first_submitted_qc>November 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2011</study_first_posted>
  <results_first_submitted>August 27, 2021</results_first_submitted>
  <results_first_submitted_qc>August 27, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 22, 2021</results_first_posted>
  <last_update_submitted>August 27, 2021</last_update_submitted>
  <last_update_submitted_qc>August 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatic Insufficiency</mesh_term>
    <mesh_term>Liver Failure</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Participants (Pts) were enrolled in Group 3 (moderate hepatic impairment) after satisfactory interim safety and pharmacokinetic (PK) data was obtained from â‰¥3 Pts in Group 2 (mild hepatic impairment). Pts were enrolled in Group 4 (severe hepatic impairment) after satisfactory interim safety and PK data was obtained from â‰¥3 Pts in Group 3.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>LY2140023-Normal Hepatic Function</title>
          <description>Participants with normal hepatic function received a single oral dose of 80 milligrams (mg) LY2140023 on Day 1.</description>
        </group>
        <group group_id="P2">
          <title>LY2140023-Mild Hepatic Impairment</title>
          <description>Participants with mild hepatic impairment received a single oral dose of 80 mg LY2140023 on Day 1.</description>
        </group>
        <group group_id="P3">
          <title>LY2140023-Moderate Hepatic Impairment</title>
          <description>Participants with moderate hepatic impairment received a single oral dose of 80 mg LY2140023 on Day 1.</description>
        </group>
        <group group_id="P4">
          <title>LY2140023-Severe Hepatic Impairment</title>
          <description>Participants with severe hepatic impairment received a single oral dose of 80 mg LY2140023on Day 1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received 1 Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Entry Criteria Not Met</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants.</population>
      <group_list>
        <group group_id="B1">
          <title>LY2140023-Normal Hepatic Function</title>
          <description>Participants with normal hepatic function received a single oral dose of 80 mg LY2140023 on Day 1.</description>
        </group>
        <group group_id="B2">
          <title>LY2140023-Mild Hepatic Impairment</title>
          <description>Participants with mild hepatic impairment received a single oral dose of 80 mg LY2140023 on Day 1.</description>
        </group>
        <group group_id="B3">
          <title>LY2140023-Moderate Hepatic Impairment</title>
          <description>Participants with moderate hepatic impairment received a single oral dose of 80 mg LY2140023 on Day 1.</description>
        </group>
        <group group_id="B4">
          <title>LY2140023-Severe Hepatic Impairment</title>
          <description>Participants with severe hepatic impairment received a single oral dose of 80 mg LY2140023on Day 1.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="9"/>
            <count group_id="B4" value="12"/>
            <count group_id="B5" value="37"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.9" spread="2.5"/>
                    <measurement group_id="B2" value="57.4" spread="5.9"/>
                    <measurement group_id="B3" value="56.8" spread="4.0"/>
                    <measurement group_id="B4" value="53.9" spread="7.3"/>
                    <measurement group_id="B5" value="56.0" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics: Area Under the Concentration Time Curve (AUC) of LY2140023 and LY404039</title>
        <description>LY404039 is the active metabolite of LY2140023. AUC from zero to infinity AUC(0-âˆž) is presented.</description>
        <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 9, 12, 16, 24, 36, and 48 hours postdose</time_frame>
        <population>All participants who received 1 dose of LY2140023, did not have an incidence of vomiting within 5 hours postdose, and had evaluable AUC(0-âˆž) data.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2140023-Normal Hepatic Function</title>
            <description>Participants with normal hepatic function received a single oral dose of 80 mg LY2140023 on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>LY2140023-Mild Hepatic Impairment</title>
            <description>Participants with mild hepatic impairment received a single oral dose of 80 mg LY2140023 on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>LY2140023-Moderate Hepatic Impairment</title>
            <description>Participants with moderate hepatic impairment received a single oral dose of 80 mg LY2140023 on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>LY2140023-Severe Hepatic Impairment</title>
            <description>Participants with severe hepatic impairment received a single oral dose of 80 mg LY2140023on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Area Under the Concentration Time Curve (AUC) of LY2140023 and LY404039</title>
          <description>LY404039 is the active metabolite of LY2140023. AUC from zero to infinity AUC(0-âˆž) is presented.</description>
          <population>All participants who received 1 dose of LY2140023, did not have an incidence of vomiting within 5 hours postdose, and had evaluable AUC(0-âˆž) data.</population>
          <units>nanograms*hours per milliliter (ng*h/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LY2140023</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1420" spread="34"/>
                    <measurement group_id="O2" value="1360" spread="30"/>
                    <measurement group_id="O3" value="836" spread="57"/>
                    <measurement group_id="O4" value="926" spread="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LY404039</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2710" spread="16"/>
                    <measurement group_id="O2" value="3290" spread="28"/>
                    <measurement group_id="O3" value="2570" spread="28"/>
                    <measurement group_id="O4" value="2640" spread="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics: Maximum Observed Drug Concentration (Cmax) of LY2140023 and LY404039</title>
        <description>LY404039 is the active metabolite of LY2140023.</description>
        <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 9, 12, 16, 24, 36, and 48 hours postdose</time_frame>
        <population>All participants who received 1 dose of LY2140023, did not have an incidence of vomiting within 5 hours postdose, and had evaluable Cmax data.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2140023-Normal Hepatic Function</title>
            <description>Participants with normal hepatic function received a single oral dose of 80 mg LY2140023 on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>LY2140023-Mild Hepatic Impairment</title>
            <description>Participants with mild hepatic impairment received a single oral dose of 80 mg LY2140023 on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>LY2140023-Moderate Hepatic Impairment</title>
            <description>Participants with moderate hepatic impairment received a single oral dose of 80 mg LY2140023 on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>LY2140023-Severe Hepatic Impairment</title>
            <description>Participants with severe hepatic impairment received a single oral dose of 80 mg LY2140023on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Maximum Observed Drug Concentration (Cmax) of LY2140023 and LY404039</title>
          <description>LY404039 is the active metabolite of LY2140023.</description>
          <population>All participants who received 1 dose of LY2140023, did not have an incidence of vomiting within 5 hours postdose, and had evaluable Cmax data.</population>
          <units>nanograms/milliliter (ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LY2140023</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="332" spread="27"/>
                    <measurement group_id="O2" value="305" spread="29"/>
                    <measurement group_id="O3" value="211" spread="41"/>
                    <measurement group_id="O4" value="194" spread="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LY404039</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="440" spread="10"/>
                    <measurement group_id="O2" value="517" spread="23"/>
                    <measurement group_id="O3" value="431" spread="28"/>
                    <measurement group_id="O4" value="403" spread="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics: Time of Maximal Concentration (Tmax) of LY2140023 and LY404039</title>
        <description>LY404039 is the active metabolite of LY2140023.</description>
        <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 9, 12, 16, 24, 36, and 48 hours postdose</time_frame>
        <population>All participants who received 1 dose of LY2140023, did not have an incidence of vomiting within 5 hours postdose, and had evaluable Tmax data.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2140023-Normal Hepatic Function</title>
            <description>Participants with normal hepatic function received a single oral dose of 80 mg LY2140023 on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>LY2140023-Mild Hepatic Impairment</title>
            <description>Participants with mild hepatic impairment received a single oral dose of 80 mg LY2140023 on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>LY2140023-Moderate Hepatic Impairment</title>
            <description>Participants with moderate hepatic impairment received a single oral dose of 80 mg LY2140023 on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>LY2140023-Severe Hepatic Impairment</title>
            <description>Participants with severe hepatic impairment received a single oral dose of 80 mg LY2140023on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Time of Maximal Concentration (Tmax) of LY2140023 and LY404039</title>
          <description>LY404039 is the active metabolite of LY2140023.</description>
          <population>All participants who received 1 dose of LY2140023, did not have an incidence of vomiting within 5 hours postdose, and had evaluable Tmax data.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LY2140023</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" lower_limit="2.00" upper_limit="4.00"/>
                    <measurement group_id="O2" value="2.50" lower_limit="2.00" upper_limit="3.00"/>
                    <measurement group_id="O3" value="2.50" lower_limit="1.00" upper_limit="4.00"/>
                    <measurement group_id="O4" value="2.00" lower_limit="2.00" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LY404039</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.00" lower_limit="3.00" upper_limit="4.00"/>
                    <measurement group_id="O2" value="4.00" lower_limit="3.00" upper_limit="4.00"/>
                    <measurement group_id="O3" value="3.50" lower_limit="2.00" upper_limit="4.00"/>
                    <measurement group_id="O4" value="4.00" lower_limit="3.00" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>LY2140023-Normal Hepatic Function</title>
          <description>Participants with normal hepatic function received a single oral dose of 80 mg LY2140023 on Day 1.</description>
        </group>
        <group group_id="E2">
          <title>LY2140023-Mild Hepatic Impairment</title>
          <description>Participants with mild hepatic impairment received a single oral dose of 80 mg LY2140023 on Day 1.</description>
        </group>
        <group group_id="E3">
          <title>LY2140023-Moderate Hepatic Impairment</title>
          <description>Participants with moderate hepatic impairment received a single oral dose of 80 mg LY2140023 on Day 1.</description>
        </group>
        <group group_id="E4">
          <title>LY2140023-Severe Hepatic Impairment</title>
          <description>Participants with severe hepatic impairment received a single oral dose of 80 mg LY2140023on Day 1.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dizziness postural</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

